ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

Despite the steep decline, ABBV’s ex-Humira platform grew more than 21% year over year (on a reported basis) in the first quarter of 2025, driven by its newer immunology drugs, Skyrizi and Rinvoq.

You know the commercial: Now you know the Tennessee Titans' 2025 schedule via "Schedule-rizi" to cure "Football Season Withdrawal." ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

MMRDA Pen Township Project: The Maharashtra government has approved a 50% concession in stamp duty for land transactions related to the Pen township project, a significant urban development initiative ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) – UC ...

The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the ...

Straight out of a "Saturday Night Live"-style sketch, Schedule-rizi is a clever play on the seemingly constant Skyrizi commercials on television. (You know the familiar Skyrizi theme even if you ...